in the event of overdose: excessive sedation, respiratory depression, coma.
Management of respiratory depression includes assisted ventilation and/or administration of naloxone. Monitor patient closely for several hours.
Administer with caution to patients with respiratory impairment, head injury, raised intracranial pressure, uncontrolled epilepsy or urethroprostatic disorders.
In elderly patients and in patients with severe renal or hepatic impairment: reduce doses by half and administer less frequently, accordingto clinical response(risk of accumulation).
Do not combine with opioid analgesics with mixed agonist-antagonist activity such as buprenorphine, nalbuphine, pentazocine (competitive action).
Increased risk of sedation and respiratory depression, when combined with alcohol and drugs acting on the central nervous system: benzodiazepines (diazepam, etc.), antipsychotics (chlorpromazine, haloperidol, etc.), antihistamines (chlorphenamine, promethazine), phenobarbital, etc.
Pregnancy and breast-feeding: no contra-indication. The child may develop withdrawal symptoms, respiratory depression and drowsiness when the mother receives morphine at the end of the 3rd trimester and during breast-feeding. In these situations, administer with caution, for a short period, at the lowest effective dose, and monitor the child.
Remarks
Administer an appropriate laxative(e.g. lactulose) if analgesic treatment continues more than 48 hours.
Morphine is on the list of narcotics: follow national regulations